Clinical trials have demonstrated its potential to reduce levels of interleukin-6 (IL-6), enhance the activity of the antioxidant enzyme GPx, and alleviate symptoms such as anxiety and depression in patients with PCC [20,185]. This evidence concerns the gene IL6 and major depressive disorder.